Latest news with #Iselin
Yahoo
3 days ago
- Business
- Yahoo
Why Middlesex Water (MSEX) is a Great Dividend Stock Right Now
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments. While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases. Based in Iselin, Middlesex Water (MSEX) is in the Utilities sector, and so far this year, shares have seen a price change of 8.44%. The water utility is currently shelling out a dividend of $0.34 per share, with a dividend yield of 2.38%. This compares to the Utility - Water Supply industry's yield of 2.53% and the S&P 500's yield of 1.54%. In terms of dividend growth, the company's current annualized dividend of $1.36 is up 3.4% from last year. Middlesex Water has increased its dividend 5 times on a year-over-year basis over the last 5 years for an average annual increase of 6.15%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Middlesex Water's current payout ratio is 56%. This means it paid out 56% of its trailing 12-month EPS as dividend. MSEX is expecting earnings to expand this fiscal year as well. The Zacks Consensus Estimate for 2025 is $2.53 per share, which represents a year-over-year growth rate of 2.43%. Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. However, not all companies offer a quarterly payout. High-growth firms or tech start-ups, for example, rarely provide their shareholders a dividend, while larger, more established companies that have more secure profits are often seen as the best dividend options. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, MSEX is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Middlesex Water Company (MSEX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Associated Press
23-05-2025
- Business
- Associated Press
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of an underwritten public offering of 9,285,714 shares of its common stock, together with accompanying warrants to purchase 18,571,428 shares of its common stock. The combined public offering price of common stock and accompanying warrant is $1.40. The common stock is being sold in combination with an accompanying warrant to purchase two shares of common stock issued for each share of common stock sold. The accompanying warrant has an exercise price of $1.40 per share, will become exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on May 27, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Outlook Therapeutics are expected to be approximately $13.0 million. Outlook Therapeutics intends to use the net proceeds from the offering for working capital and other general corporate purposes. BTIG, LLC is acting as sole book-running manager for the offering. The securities described above are being offered by Outlook Therapeutics pursuant to a shelf registration statement on Form S-3 (No. 333-278340) that was declared effective by the Securities and Exchange Commission (SEC) on April 5, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at Copies of the preliminary prospectus supplement and the final prospectus supplement relating to this offering may be obtained, when available, by contacting: BTIG, LLC, 65 East 55th Street, New York, New York 10022, by telephone at (212) 593-7555 or by email at [email protected]. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and Medicines and Healthcare products Regulatory Agency Marketing Authorization for the treatment of wet age-related macular degeneration (wet AMD). Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the European Union and the United Kingdom as a treatment for wet AMD, expected in the second quarter of calendar year 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, and a Biologics License Application has been resubmitted to the U.S. Food and Drug Administration. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as 'anticipate,' 'believe,' 'continue,' 'expect,' 'may,' 'plan,' 'potential,' 'will,' or 'would' the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, statements regarding the gross proceeds from the offering, the use of proceeds from the offering, the completion of the offering, expectations concerning decisions of regulatory bodies and the timing thereof, plans for commercial launch of LYTENAVA™ in the EU and the UK and the timing thereof and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include fluctuations in Outlook Therapeutics' stock price, changes in market conditions and satisfaction of customary closing conditions related to the offering, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, and the sufficiency of Outlook Therapeutics' resources, as well as those risks detailed in Outlook Therapeutics' filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the SEC on December 27, 2024, and subsequent filings with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. Investor Inquiries: Jenene Thomas Chief Executive Officer JTC Team, LLC T: 908.824.0775 [email protected] Source: Outlook Therapeutics, Inc.
Yahoo
31-01-2025
- Health
- Yahoo
Insurers: Mass. health care reaching 'limits of affordability'
BOSTON (SHNS) – Confronting soaring health care costs compounded by widespread obstacles in accessing care, top insurance executives warned Thursday that the state's health care system is at a breaking point. New payment models could help alleviate the industry's financial woes, particularly in the primary care landscape, they said. The heads of Blue Cross Blue Shield of Massachusetts, Fallon Health and WellSense Health Plan offered their sobering perspectives on cost and access challenges in front of hundreds of health care providers gathered at the Massachusetts Health and Hospital Association's annual meeting at the Westin Seaport. 'The challenges, no matter where you sit in the health care ecosystem right now, are profound,' Sarah Iselin, CEO of Blue Cross Blue Shield of Massachusetts, said during a panel discussion. Iselin invoked nearly double-digit health care cost trends, which she attributed to steeper medications prices like GLP-1 weight-loss drugs and 'higher utilization increases across the board.' Iselin said those trends are driving losses among health insurers. Blue Cross had a 'pretty rough' last year, and that trend is expected through 2025, she said. 'It is going to have consequences that I think should concern all of the local payers because the faster health care costs grow, the more tempting it is for employers to go self-insured,' said Iselin, who warned that would 'invite more of the national payers into the market.' Echoing Iselin's assessment, Fallon Health CEO Manny Lopes said both providers and payers are at a 'crisis point.' Meanwhile, WellSense Health Plan President Heather Thiltgen said Massachusetts is 'really starting to reach the limits of affordability, for our consumers, our employers and our taxpayers.' Panelists also discussed initiatives their organizations are pursuing to manage health care costs and bolster access, with an eye toward pinpointing potential statewide strategies. Assistant Secretary for MassHealth Mike Levine said state officials over the last two years 'significantly increased' investment in primary care by embracing a capitated payment model rather than a fee-for-service structure. That move creates a more predictable monthly revenue stream for primary care practices, Levine said. 'I don't think there are enough practices in Massachusetts with a high enough Medicaid payer mix for that to be the thing alone that will transform care and experience for providers and members,' Levine said. 'But we are eager to partner with providers and other payers to build a model of capitation in the primary care setting that will hopefully unlock some of the access that has been so hard to find.' Gov. Maura Healey and Senate President Karen Spilka have pegged primary care as a priority for the new legislative session. A primary care task force, established through the new hospital oversight law, will produce recommendations to improve care access, delivery and financial sustainability. Healey, during remarks earlier Thursday at the MHA meeting, said her fiscal 2026 budget proposal looks to boost MassHealth investment in primary care to '10% of its total spend moving forward.' 'We know that without that proper investment, we can't support our primary care workforce, we can't give patients better access to the care they deserve,' the governor said. 'And we think there's an opportunity for all of us together to look at how we can prioritize primary care.' Lopes highlighted another capitated program at Fallon Health, which he said serves the frailest elderly members who are considered eligible for nursing homes but receive comprehensive at-home care. 'The goal is to try to keep those individuals out of institutions, living in the community and living healthy in the community, and bring all the support services for them and their families,' Lopes said. 'When I look at that model, it really is a model that we can apply to other frail populations or severely ill populations, where we really create an environment of capitated payment — create an environment where someone can come in and get the care that they need.' Thiltgen said WellSense, which serves a large share of people with Medicaid and highly-subsidized ConnectorCare coverage, said members have 'considerable access problems' for behavioral and primary care. She said the health plan is exploring how to better integrate care, including for individuals with substance use disorder. 'We are experimenting with putting nurse practitioners in providers' offices so that we can help providers more efficiently understand who needs the care, and provide that bridge and help improve overall quality,' Thiltgen said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
